Y. Hotko

发表

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.

K. O'Byrne, R. Ramlau, J. von Pawel, 2011, The Lancet. Oncology.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase III, Randomized, Double‐Blind, Placebo‐Controlled Trial of Pegfilgrastim in Patients Receiving First‐Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti‐VEGF Evaluation Study (PAVES)

P. Gibbs, J. Jassem, Y. Hotko, 2017, Clinical colorectal cancer.

Phase III study (20050181) of panitumumab with FOLFIRI compared to FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer: preliminary safety results.

F. Lordick, M. Ducreux, Y. Hotko, 2008 .

Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

E. Van Cutsem, F. Lordick, C. Punt, 2014 .

Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, C. Punt, M. Ducreux, 2014 .

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Hua Yu, Gregory Wilson, 2015, Clinical Cancer Research.

Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).

F. Lordick, M. Ducreux, Y. Hotko, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results

F. Lordick, M. Ducreux, Y. Hotko, 2008 .

14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

F. Lordick, M. Ducreux, Y. Hotko, 2009 .

The Significance Of Hormone Receptors In Male Breast Cancer

Y. Hotko, 2020 .

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

Y. Hotko, K. Syrigos, M. Gumus, 2021, BioDrugs.

Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

M. Socinski, Y. Hotko, J. Singer, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Male breast cancer: clinical presentation, diagnosis, treatment.

Y. Hotko, 2013, Experimental oncology.

Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study.

K. O'Byrne, I. Bondarenko, C. Barrios, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial

P. Neven, Y. Hotko, H. Denys, 2023, Cancer Research.

PATIENT MANAGEMENT TACTICS AT DIFFERENT STAGES OF GASTROINTESTINAL STROMAL TUMORS (GIST).

Y. Hotko, Myroslav V Rosul, S. V. Zhero, 2023, Wiadomosci lekarskie.

Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, M. Ducreux, Y. Hotko, 2012 .

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

R. Epstein, M. Campone, I. Bondarenko, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

F. Lordick, M. Ducreux, Y. Hotko, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

T. Crocenzi, Tae-You Kim, Y. Hotko, 2024, Annals of oncology : official journal of the European Society for Medical Oncology.